Physician profile
Scott D Barton
NPI 1376690180
$2,851.64
in general payments reported to CMS, 2019-2025
33 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $389 · 2021: $351 · 2022: $700 · 2023: $401 · 2024: $243 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $872.68 | 2021-2025 | Vraylar, Qulipta |
| Amgen INC. | $385.61 | 2019-2024 | Krystexxa |
| Pfizer INC. | $193.23 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $172.35 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Novo Nordisk INC | $125.65 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.18 | 2020 | |
| Novartis Pharmaceuticals Corporation | $99.76 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.83 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $86.68 | 2019-2023 | Spravato |
| Boston Scientific Corporation | $81.59 | 2020-2023 | |
| Dynavax Technologies Corporation | $64.01 | 2019 | |
| Horizon Therapeutics Plc | $57.14 | 2021-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $53.80 | 2019-2025 | Shingrix |
| Amarin Pharma, INC. | $46.92 | 2019-2020 | |
| Organon LLC | $44.27 | 2023-2025 | Nexplanon |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $40.54 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.46 | 2022 | |
| Rgh Enterprises LLC | $24.00 | 2025 | |
| Quidel Corporation | $23.92 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.24 | 2022 | |
| Nevro Corp. | $22.38 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.18 | 2023 | |
| Allergan, INC. | $20.78 | 2019 | |
| Lucid Diagnostics INC. | $18.89 | 2023 | |
| Kaleo, INC. | $18.61 | 2022 | |
| Sumitomo Pharma America, INC. | $17.23 | 2024 | Gemtesa |
| Bausch Health US, LLC | $16.85 | 2023 | Aplenzin |
| Becton, Dickinson and Company | $15.88 | 2022 | |
| Abbott Laboratories | $15.66 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.92 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.00 | 2021 | |
| Antares Pharma, INC. | $13.87 | 2024 | Xyosted |
| Daiichi Sankyo INC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.